Tasly Pharmaceutical Group

Traditional Chinese medicine, cardiovascular franchise

600535 · SSE · China

Public Market Listing

600535SSE

SSE primary exchange listing

Live quotes, historical charts, and market capitalization for Tasly Pharmaceutical Group are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(6 total)
6Total Assets
0Approved
2Phase 3 / Filed
4Phase 1–2 / Early
5Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
Phase 3
Traditional Chinese medicine (multi-component)Botanical
Heart FailureChronic Kidney Disease
Phase 3
Mesenchymal precursor cells (MPCs)Cell therapy
Heart FailureChronic Low Back Pain
Phase 2
PD-L1 / VEGFMultispecific antibody
Non-Small Cell Lung Cancer
Phase 2
Multi-target (ginsenoside)Botanical
Heart Failure
Phase 2
Traditional Chinese medicine (multi-component)Small molecule
Psoriasis
Phase 1/2
Cardiac cell therapyCell therapy
Heart Failure

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
HucMSC intramyocardial therapyPhase 1/2Coronary Artery Bypass Grafting (CABG), Chronic Heart Failure, Chronic Ischemic Cardiomyopathy
Est. primary completion 2026-12-31 · NCT07265349 · CT.gov ↗
What to watch
Jia Shen TabletPhase 2Heart Failure
Est. primary completion 2026-12-31 · NCT06669169 · CT.gov ↗
What to watch
2027 (1)
July 2027 (1)
rexlemestrocel-LPhase 3Degenerative Disc Disease
Est. primary completion 2027-07 · NCT06325566 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
QiShenYiQiPhase 3Heart Failure
Est. primary completion 2028-06-22 · NCT07687186 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 June 2026Filing submittedrexlemestrocel-LMesoblast received a BLA filing number and requested modular review for rexlemestrocel-L in LVAD patients
US, FDA · Source ↗

Financial reports

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.1B$118M——report ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-9M$882M$77M$366M—report ↗
2024-FY$1.2B—$410M—report ↗
2023-FY$1.2B———report ↗